Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 297

Similar articles for PubMed (Select 12860952)

1.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G.

J Clin Oncol. 2003 Jul 15;21(14):2732-9. Erratum in: J Clin Oncol.2008 Apr 20;26(12): 2066.

PMID:
12860952
2.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
3.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A; Greek Myeloma Study Group.

Ann Oncol. 2004 Jan;15(1):134-8.

4.

Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.

Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C.

J BUON. 2007 Jan-Mar;12(1):41-4.

PMID:
17436400
5.

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.

Alexanian R, Weber D, Giralt S, Delasalle K.

Ann Oncol. 2002 Jul;13(7):1116-9.

6.

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.

Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.

Br J Haematol. 2010 Feb;148(4):562-8. doi: 10.1111/j.1365-2141.2009.07981.x. Epub 2009 Nov 16.

PMID:
19919652
7.

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.

Eur J Haematol. 2006 Apr;76(4):273-7.

PMID:
16519697
8.

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.

Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A.

Hematol J. 2004;5(2):112-7.

PMID:
15048060
9.

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.

Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL.

Br J Haematol. 2006 Jan;132(2):155-61.

PMID:
16398649
10.
11.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

12.

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.

Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G.

Clin Lymphoma. 2003 Jun;4(1):32-5.

PMID:
12837152
13.

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G.

Blood. 2001 Sep 1;98(5):1614-5.

14.

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.

Dmoszynska A, Walter-Croneck A, Hus I, Grzasko N, Manko J, Jedrzejczak WW, Charlinski G, Usnarska-Zubkiewicz L, Skotnicki A, Wolska-Smolen T, Piszcz J, Kloczko J.

Leuk Res. 2010 Oct;34(10):1330-5. doi: 10.1016/j.leukres.2010.05.003. Epub 2010 Jun 2.

PMID:
20627385
15.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N.

Ann Oncol. 2001 Jul;12(7):991-5.

16.
17.

CODBLAM IV chemotherapy for large cell lymphoma: sequential use of infusional vincristine and bleomycin and "high dose" consolidation.

Rafi S, Coleman M, Kaufmann T, Cesarman G, Papish SW, Bernhart B, Gaynor M, Reisman AM.

Am J Clin Oncol. 1997 Feb;20(1):90-6.

PMID:
9020298
18.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

19.

Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.

Zemanova M, Scudla V, Adam Z, Gregora E, Pour L, Minarik J, Pavlicek P, Pika T, Bacovsky J.

Neoplasma. 2008;55(4):345-9.

PMID:
18505347
20.

Transplantation as salvage therapy for high-risk patients with myeloma in relapse.

Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.

Bone Marrow Transplant. 2002 Dec;30(12):873-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk